Twinrix Paediatric


hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 14/01/2022

Authorisation details

Product details
Twinrix Paediatric
Agency product number
Active substance
  • hepatitis A virus (inactivated)
  • hepatitis B surface antigen
International non-proprietary name (INN) or common name
hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)
Therapeutic area (MeSH)
  • Immunization
  • Hepatitis B
  • Hepatitis A
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
GlaxoSmithKline Biologicals S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Rue de l'Institut, 89
B-1330 Rixensart

Product information

13/01/2022 Twinrix Paediatric - EMEA/H/C/000129 - WS2155

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Twinrix Paediatric is indicated for use in non-immune infants, children and adolescents from one year up to and including 15 years who are at risk of both hepatitis-A and hepatitis-B infection.

Assessment history

How useful was this page?

Add your rating